These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 15949566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
    Miglino M, Varaldo R, Colombo N, Grasso R, Clavio M, Garuti A, Aquino S, Albarello A, Sessarego M, Gobbi M.
    J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
    [Abstract] [Full Text] [Related]

  • 5. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
    Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C.
    Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):111-5. PubMed ID: 17452251
    [Abstract] [Full Text] [Related]

  • 9. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B.
    Cancer Genet Cytogenet; 2005 Jun 15; 159(2):164-7. PubMed ID: 15899391
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL, Megat Baharuddin PJ, Chin LP, Zakaria Z, Yegappan S, Sathar J, Tan SM, Purushothaman V, Chang KM.
    Cancer Genet Cytogenet; 2008 Jan 01; 180(1):60-4. PubMed ID: 18068536
    [Abstract] [Full Text] [Related]

  • 12. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 13. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengió R, Larripa I.
    Eur J Haematol; 2009 Apr 15; 82(4):292-300. PubMed ID: 19191867
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M, Ristic S, Pavlovic S, Colovic M.
    Leuk Res; 2009 Jun 15; 33(6):e10-2. PubMed ID: 19091403
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrão AC, Bentes IR, Azevedo TC, Maradei-Pereira LM.
    Genet Mol Res; 2005 Dec 30; 4(4):803-11. PubMed ID: 16475128
    [Abstract] [Full Text] [Related]

  • 18. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S.
    Genes Chromosomes Cancer; 2008 Oct 30; 47(10):919-21. PubMed ID: 18615681
    [No Abstract] [Full Text] [Related]

  • 19. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, Abraham A, George B, Srivastava A, Srivastava VM, Mathews V, Balasubramanian P.
    Int J Lab Hematol; 2017 Jun 30; 39(3):235-242. PubMed ID: 28035733
    [Abstract] [Full Text] [Related]

  • 20. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Irvani M, Bahar B, Bibordi I.
    Arch Iran Med; 2008 May 30; 11(3):247-51. PubMed ID: 18426313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.